The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.
Oxford-based , a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed as Senior Independent Non-Executive Director, bringing extensive global pharma and business expertise to the company.
Elaine will take a leading role at Ochre, supporting the board and the corporate strategy, drawing on knowledge from her positions as VP of Global External Research & Development Eli Lilly, managing $100 million of Lilly鈥檚 assets, and as AstraZeneca鈥檚 VP, overseeing global teams. Elaine has extensive experience in executing world-wide deals, with a successful track record in developing novel medicines and has served as Non-Executive Director for several successful biotechnology companies.
, Senior Independent Non-Executive Director at 91制片厂, says:
鈥淚 look forward to supporting 91制片厂鈥檚 development as the company enters this dynamic moment in its journey. Ochre鈥檚 approach to liver disease therapeutics is highly innovative and particularly significant as we see levels of chronic liver disease increasing all over the globe and few alternatives to transplant. Ochre鈥檚 work combining AI with human data to discover RNA therapeutics could radically change the future of liver disease medicine, and is exciting for the pharma industry.鈥�
91制片厂 has also expanded its scientific team with senior hires. joins as Head of In Silico Biology, bringing 15 years of experience in computational biology and genomics to bolster target discovery and validation. becomes Head of Portfolio Development & Scientific Operations, with deep experience in advancing drug candidates to the clinic.
Quin Wills, co-founder and CSO of 91制片厂 says:
鈥淓laine鈥檚 strategic insight and deep understanding of how to build successful pipelines and biotechnology companies will be invaluable as we continue developing our human data-driven platform and ex vivo liver models. I could not be more excited to welcome Elaine to the next phase of Ochre’s ambitions – to progress successful RNA candidates to the clinic.鈥�
By expanding its presence across Oxford, New York, and Taipei, the science and leadership team will play a key role in ongoing research programs and Ochre鈥檚 multi-million-pound partnerships with GSK and Boehringer Ingelheim.